Clinical trial
AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects…
NCT00135317 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00135317 |
|---|---|
| Title | AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies |
| Official title | A Randomized Open-Label Study of Darbepoetin Alfa Administered Every Three Weeks With or Without Parenteral Iron in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | darbepoetin alfa |
| Start date | Nov 1, 2004 |
| First posted | Aug 26, 2005 |
| Last update posted | May 23, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: